Aung Naing

This roundtable will explore how bidirectional translational research can be more effectively used to inform bispecific drug development across discovery, preclinical, and clinical stages. Participants will discuss how to better integrate biological understanding within specific disease contexts, refine in vitro models to improve predictive value, and close mechanistic gaps through real-time feedback between clinical and nonclinical functions. The discussion will also consider how costimulatory pathways and immune modulators can be evaluated to fine-tune bispecific functionality and therapeutic outcomes.

• How can we improve communication and alignment between translational, preclinical, and clinical teams during bispecific development?
• In what ways can in vitro design and validation be enhanced to more accurately predict in vivo pharmacology and safety?
• What are the biggest current gaps in mechanistic understanding of bispecifics that hinder clinical translation?
• How do we assess whether immune modulatory and costimulatory signals are functioning as expected in early development?
• What models or translational strategies have proven most effective in iterating bispecific designs for specific disease settings?